RGNX
Regenxbio Inc
7.40$
+0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -170.9% | -183.5% | -355.0% | -204.1% | -167.6% | -149.1% | 37.8% | -231.0% | -188.2% | -172.4% | -1,191.7% | -57.6% | -141.4% | |
| 15.1% | 19.5% | 26.8% | 18.2% | 16.4% | 19.0% | 4.4% | 18.3% | 13.1% | 12.8% | 60.3% | 3.5% | 8.8% | |
| 35.3% | 37.5% | 61.5% | 42.3% | 40.8% | 45.0% | 9.6% | 40.5% | 30.3% | 27.6% | 134.8% | 8.4% | 20.1% | |
| -2.2% | 41.5% | -52.2% | -18.1% | 25.1% | 54.9% | 18.4% | 35.3% | -34.9% | -5.9% | -23.5% | -95.6% | -67.0% | |
| 5.0% | 5.1% | 3.6% | 2.1% | 1.3% | 5.1% | 1.2% | 1.8% | 1.7% | 1.7% | 19.3% | 0.7% | 1.7% | |
| 133.7% | 152.9% | 84.4% | -1.2% | 207.7% | 189.8% | 50.3% | -657.5% | 142.2% | 123.7% | 1,104.1% | 61.0% | 124.0% | |
| 4.3% | – | 2.6% | – | 3.2% | – | 0.3% | – | 2.5% | – | – | – | – | |
| – | – | – | – | – | – | – | – | -0.1% | 0.0% | – | – | – | |
| -16.6% | -53.9% | 772.8% | -42.4% | -44.9% | -36.5% | -6.5% | 651.9% | -23.8% | -31.6% | -213.3% | 16.3% | -7.3% | |
| -53.8% | -83.4% | 502.2% | -247.6% | -4.7% | 4.3% | 81.5% | -236.6% | -69.8% | -80.2% | -300.9% | 19.7% | -24.7% | |
| -175.9% | -188.6% | -358.5% | -206.2% | -168.9% | -154.2% | 36.6% | -232.8% | -189.9% | -174.0% | -1,211.0% | -58.3% | -143.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.